drugset / Trial / NCT03881774
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
NaSingle-groupOpen-labelTreatment
Summary
Evaluation the safety and efficacy of cord blood-derived CAR-T cells in patients with relapsed/refractory B cell leukemia/lymphoma whose disease relapsed after autologous CAR-T cells therapy or who fail to preparation for autologous CAR-T cells
Timeline
- Start
- 2019-02-27
- Primary completion
- 2021-01-31
- Completion
- 2022-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | CAR-T cells | Cell therapy | 3e+06 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Cyclophosphamide | Other / unclassified | 800 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |